GE HealthCare beats on earnings, slashes full year outlook due to tariffs

GE HealthCare beats on earnings, slashes full year outlook due to tariffs


GE HealthCare reported better-than-expected first-quarter results on Wednesday, but the company slashed its annual forecast to account for the impact of President Donald Trump’s far-reaching “reciprocal” tariff policy.

Shares of GE HealthCare were up 3% on Wednesday.

Here’s how the company did:

  • Earnings per share: $1.01 adjusted vs. 91 cents expected by LSEG.
  • Revenue: $4.78 billion vs. $4.66 billion expected by LSEG.

Revenue increased 3% year over year from $4.65 billion. GE HealthCare reported net income of $564 million, or $1.23 per share, up from $374 million, or 81 cents per share, during the same period last year.

GE HealthCare’s adjusted EPS figure is a result of adds like nonoperating benefit costs, restructuring costs and investment valuations, among other things.

For its full year, GE HealthCare said it expects to report adjusted earnings in the range of $3.90 to $4.10 per share, which is a decline of 13% to 9% from its guide last quarter. The company said the range includes roughly 85 cents per share of tariff impact.

“Regarding the current global trade environment, we are actively driving mitigation actions,” GE HealthCare CEO Peter Arduini said in a statement. “We continue to see strong customer demand in many of the markets we serve and are well-positioned to drive long-term value as we invest in future innovation.”

Stock Chart IconStock chart icon

hide content

GE HealthCare’s stock over a one month period.

GE HealthCare sells a range of medical technology, pharmaceutical diagnostics, imaging solutions, artificial intelligence tools and data analytics solutions. The company manufactures its products in 20 countries and serves customers in more than 160 nations around the globe, according to its website.

On April 2, Trump introduced his tariff policy, which initially established a 10% baseline levy on almost every country, though many nations such as China, Vietnam and Taiwan were subject to much steeper rates. Days later, Trump dropped those steeper rates to 10% for 90 days to allow trade negotiations with those countries.

China remains a notable exception, as Trump has imposed cumulative tariffs of 145% on Chinese goods this year. This brings the total tariffs on some products from China to as high as 245%, according to a fact sheet released by the White House.

GE HealthCare has a substantial presence in China, and Arduini told investors Wednesday that the company has “conservatively assumed” that the bilateral U.S. and China tariffs will account for 75% of its total net tariff impact.

The company announced in February that Johnson & Johnson veteran Will Song will lead its China business as CEO starting in July.

Don’t miss these insights from CNBC PRO

GE Healthcare CEO Peter Arduini talks AI investments



Source

Cigna announces new deal for copay caps on Eli Lilly and Novo Nordisk weight loss drugs
Health

Cigna announces new deal for copay caps on Eli Lilly and Novo Nordisk weight loss drugs

Wegovy injection pens arranged in Waterbury, Vermont, US, on Monday, April 28, 2025. Shelby Knowles | Bloomberg | Getty Images Only half of health insurer Cigna‘s clients currently cover the popular GLP-1 weight loss drugs Wegovy and Zepbound because of their high costs. But the company’s pharmacy benefits unit Evernorth has reached a deal with […]

Read More
Cardiac arrests on the job are rising and often fatal. Workers and employers are not prepared for the risk
Health

Cardiac arrests on the job are rising and often fatal. Workers and employers are not prepared for the risk

In January 2023, Buffalo Bills safety Damar Hamlin’s shocking collapse during an NFL Monday Night Football game due to cardiac arrest placed a high-profile spotlight on a concerning, and growing, statistic: each year, more than 10,000 people suffer from cardiac arrests in U.S. workplaces.   But unlike Hamlin, whose unique workplace allowed him to receive immediate […]

Read More
Healthy Returns: Novavax scores narrower Covid vaccine approval after delay
Health

Healthy Returns: Novavax scores narrower Covid vaccine approval after delay

A health worker prepares a dose of the Novavax vaccine as the Dutch Health Service Organization starts with the Novavax vaccination program on March 21, 2022 in The Hague, Netherlands. Patrick Van Katwijk | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight […]

Read More